
Sign up to save your podcasts
Or


The founders of German biotechnology company BioNTech were researching how to fight cancers using messenger RNA, "the unloved cousin of DNA", when covid-19 first appeared and they realised mRNA could be used to make a vaccine for the disease. Financial Times journalist Joe Miller has been following the company since just before the pandemic and tells Rebecca Kesby how they created the first covid-19 vaccine. Could mRNA help cure other diseases and improve vaccine access to low income countries? We ask Oksana Pyzik of the UCL School of Pharmacy. And how might the technology change the whole pharmaceutical industry? We hear from Dr Richard Torbett, CEO of the Association of the British Pharmaceutical Industry.
Producer: Benjie Guy
(Picture: a collection of mRNA covid vaccines. Credit: Getty Images.)
By BBC World Service4.4
488488 ratings
The founders of German biotechnology company BioNTech were researching how to fight cancers using messenger RNA, "the unloved cousin of DNA", when covid-19 first appeared and they realised mRNA could be used to make a vaccine for the disease. Financial Times journalist Joe Miller has been following the company since just before the pandemic and tells Rebecca Kesby how they created the first covid-19 vaccine. Could mRNA help cure other diseases and improve vaccine access to low income countries? We ask Oksana Pyzik of the UCL School of Pharmacy. And how might the technology change the whole pharmaceutical industry? We hear from Dr Richard Torbett, CEO of the Association of the British Pharmaceutical Industry.
Producer: Benjie Guy
(Picture: a collection of mRNA covid vaccines. Credit: Getty Images.)

7,913 Listeners

4,225 Listeners

1,067 Listeners

296 Listeners

427 Listeners

5,576 Listeners

1,808 Listeners

2,113 Listeners

357 Listeners

427 Listeners

52 Listeners

227 Listeners

238 Listeners

346 Listeners

235 Listeners

684 Listeners

232 Listeners

326 Listeners

3,245 Listeners

73 Listeners

689 Listeners

528 Listeners

630 Listeners

394 Listeners

41 Listeners

239 Listeners

54 Listeners

146 Listeners

80 Listeners

96 Listeners